Drug Profile


Alternative Names: SB 217242

Latest Information Update: 15 Nov 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-ischaemics; Carboxylic acids; Heart failure therapies; Indans
  • Mechanism of Action Endothelin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Heart failure; Pulmonary hypertension; Renal failure; Reperfusion injury; Stroke

Most Recent Events

  • 15 Nov 2001 Discontinued-I for Congestive heart failure in Canada (PO)
  • 15 Nov 2001 Discontinued-II for Congestive heart failure in USA (PO)
  • 15 Nov 2001 Discontinued-II for Pulmonary hypertension in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top